Helix BioPharma (TSX:HBP) ROCE % : -1,939.39% (As of Jan. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Helix BioPharma's annualized ROCE % for the quarter that ended in Jan. 2024 was -1,939.39%.

Helix BioPharma ROCE % Historical Data

The historical data trend for Helix BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma ROCE % Chart

Helix BioPharma Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

ROCE %

Get a 7-Day Free Trial

-602.77

-2,567.06

Helix BioPharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-695.81	-339.94	-25,305.88	-	-1,939.39

Helix BioPharma ROCE % Calculation

Helix BioPharma's annualized ROCE % for the fiscal year that ended in Jul. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	-6.276	/	( ( (3.731 - 3.412)	+	(1.029 - 1.874) )	/ 2 )
	=	-6.276	/	( (0.319	+	-0.845)	/ 2 )
	=	-6.276	/	-0.263
	=	2,386.31 %

Helix BioPharma's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-3.52	/	( ( (1.895 - 1.273)	+	(0.344 - 0.603) )	/ 2 )
	=	-3.52	/	( ( 0.622	+	-0.259 )	/ 2 )
	=	-3.52	/	0.1815
	=	-1,939.39 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Helix BioPharma (TSX:HBP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Helix BioPharma ROCE % Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma (TSX:HBP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HBPCF:USA

Address

401 Bay Street, Suite 2704, Toronto, ON, CAN, M5H 2Y

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.